# Information For the User Metoprolol Succinate (25mg) ER Metoperil XL 25

Brand Name: Metoperil XL 25 Tablet Dosage Form: Extended Release Tablet Therapeutic Category: Beta-Blocker / Antihypertensive

# **Composition**:

Each uncoated extended-release tablet contains:

- Metoprolol Succinate I.P. 25 mg (in extended-release form)
- **Excipients** q.s.

# **Description**:

Metoperil XL 25 Tablet contains **Metoprolol Succinate**, a selective  $\beta$ 1-blocker used for cardiovascular conditions. The extended-release formulation provides a consistent therapeutic effect over 24 hours, improving patient compliance in long-term therapy.

# Indications:

- Mild to moderate hypertension
- Angina pectoris
- Heart failure (stable, symptomatic)
- Prevention of **myocardial infarction**

# **Mechanism of Action**:

Metoprolol selectively blocks  $\beta$ 1-adrenergic receptors, primarily in cardiac tissue. It reduces heart rate, myocardial contractility, and cardiac output, thereby lowering blood pressure and oxygen demand.

# **Dosage and Administration**:

As directed by the physician. Usual starting dose: 25–100 mg once daily depending on condition and response. Tablet should be swallowed whole; do not crush or chew.

#### **Contraindications**:

- Hypersensitivity to Metoprolol
- Sinus bradycardia, heart block (second/third degree)
- Acute heart failure or cardiogenic shock

# **Precautions**:

- Use with caution in patients with asthma, diabetes, or hepatic impairment
- Avoid abrupt withdrawal
- Monitor blood pressure and ECG regularly during treatment

#### Adverse Reactions:

- Dizziness, fatigue, bradycardia
- Cold extremities, GI disturbances
- Rare: depression, rash

# Storage:

Store in a cool and dry place, protected from light and moisture. Keep below 25°C.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd. (An ISO 9001: 2015 Certified Co.) Plot no.: 367-FF, Industrial Area Phase-I, Panchkula-134113 TM: Trademark Applied for